Evidence map›Paper›PMID 34562237›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.

Patrick Holmes, Heather Elizabeth Bell, Karan Bozkurt, Andrei-Mircea Catarig, Alice Clark, Alena Machell, Thozhukat Sathyapalan

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03876015. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03876015 completed

A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Ran2019Enrolled215Registered outcomes18Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armssemaglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Observational
  11. Review
  12. Observational
  13. Article
  14. Observational
  15. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
    Observational
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Patrick HolmesSt George's Medical Practice, Yarm Road, Darlington, DL2 1BY, UK. patrickholmes@nhs.net.ORCID http://orcid.org/0000-0002-6401-663X
Heather Elizabeth BellOld School Surgery, Greenisland, Northern Ireland, UK.
Karan BozkurtNovo Nordisk Ltd, London, UK.
Andrei-Mircea CatarigNovo Nordisk A/S, Søborg, Denmark.
Alice ClarkNovo Nordisk A/S, Søborg, Denmark.
Alena MachellEgremont Medical Centre, Wallasey, UK.
Thozhukat SathyapalanAcademic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
Novo Nordisk (Denmark) · DKNovo Nordisk (United Kingdom) · GBSt George's Hospital · GBUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOnce-weekly (OW) semaglutide was associated with clinically relevant improvements in glycaemic control and body weight versus comparators in the SUSTAIN randomised controlled trials (RCTs). SURE UK, which is one of a series of individual studies that comprise the SURE programme, evaluated the use of OW semaglutide in a real-world patient population with type 2 diabetes (T2D) in the UK.

methodsIn this prospective, observational study, adults (≥ 18 years) with ≥ 1 documented glycated haemoglobin (HbA

resultThe estimated mean change in HbA

conclusionPatients receiving OW semaglutide experienced statistically significant and clinically relevant reductions from baseline in HbA

trial registrationClinicalTrials.gov Identifier NCT03876015.

Indexed as

Glucagon-like peptide-1 receptor agonistReal-world evidenceSemaglutideType 2 diabetes

Identifiers

PMID34562237
PMCPMC8475854
OpenAlexW3200641447

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.